EarningsF3Q EPS $0.92 beat Baird/Consensus $0.82/$0.84, +22% Y/Y. Sales $928M beat Baird/Consensus $888M/$916M, with pricing +2%, volume +5pp, and FX -1pp.
GuidanceFY24 guidance raised, mostly on F3Q beat. FY24 EPS guidance upped to $3.33-$3.39, or +2pp/$0.08 at midpoint from prior $3.24-$3.32 (cons. $3.28).
Strategic MovesDCI issued a press release announcing its definitive agreement to pursue a 49% stake in Medica S.p.A., which would deepen DCI's technology base, most relevant to Life Sciences applications.